Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 22, 2022 - Issue 10
Submit an article Journal homepage
165
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Therapeutic plasma exchange for myasthenia gravis, Guillain-Barre syndrome, and other immune-mediated neurological diseases, over a 40-year experience

Mireya Fernández-Fourniera Neuroimmunology and Multiple Sclerosis Unit, Department of Neurology, Hospital Universitario La Paz & Institute for Health Research–IdiPAZ (La Paz University Hospital–Universidad Autónoma de Madrid), SpainCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-4885-0181
ORCID Icon,
Ana Kerguelenb Apheresis Unit, Department of Haematology, Hospital Universitario La Paz, SpainORCID Iconhttps://orcid.org/0000-0002-4928-6586
ORCID Icon,
Francisco Javier Rodríguez de Riveraa Neuroimmunology and Multiple Sclerosis Unit, Department of Neurology, Hospital Universitario La Paz & Institute for Health Research–IdiPAZ (La Paz University Hospital–Universidad Autónoma de Madrid), SpainORCID Iconhttps://orcid.org/0000-0001-9008-7629
ORCID Icon,
Laura Lacruza Neuroimmunology and Multiple Sclerosis Unit, Department of Neurology, Hospital Universitario La Paz & Institute for Health Research–IdiPAZ (La Paz University Hospital–Universidad Autónoma de Madrid), SpainORCID Iconhttps://orcid.org/0000-0002-7415-2395
ORCID Icon,
Santiago Jimenob Apheresis Unit, Department of Haematology, Hospital Universitario La Paz, Spain
,
Itsaso Losantosc Biostatistics Section, Hospital Universitario La Paz & Institute for Health Research–IdiPAZ (La Paz University Hospital–Universidad Autónoma de Madrid), SpainORCID Iconhttps://orcid.org/0000-0001-5338-7438
ORCID Icon,
Dolores Hernández-Maraverb Apheresis Unit, Department of Haematology, Hospital Universitario La Paz, Spain
,
Inmaculada Puertasa Neuroimmunology and Multiple Sclerosis Unit, Department of Neurology, Hospital Universitario La Paz & Institute for Health Research–IdiPAZ (La Paz University Hospital–Universidad Autónoma de Madrid), SpainORCID Iconhttps://orcid.org/0000-0002-9567-1274
ORCID Icon,
Antonio Tallon-Barrancoa Neuroimmunology and Multiple Sclerosis Unit, Department of Neurology, Hospital Universitario La Paz & Institute for Health Research–IdiPAZ (La Paz University Hospital–Universidad Autónoma de Madrid), Spain
,
Aurora Viejob Apheresis Unit, Department of Haematology, Hospital Universitario La Paz, Spain
,
Ana Frank Garcíaa Neuroimmunology and Multiple Sclerosis Unit, Department of Neurology, Hospital Universitario La Paz & Institute for Health Research–IdiPAZ (La Paz University Hospital–Universidad Autónoma de Madrid), SpainCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-3858-9116
ORCID Icon &
Exuperio Díez-Tejedora Neuroimmunology and Multiple Sclerosis Unit, Department of Neurology, Hospital Universitario La Paz & Institute for Health Research–IdiPAZ (La Paz University Hospital–Universidad Autónoma de Madrid), SpainORCID Iconhttps://orcid.org/0000-0003-2295-1707
ORCID Icon show all
Pages 897-903 | Received 14 Jun 2022, Accepted 11 Nov 2022, Published online: 30 Nov 2022

References

  • Abel JJ, Rowntree LG, Turner BB. Plasma removal with return of corpuscles (plasmaphaeresis). The Journal of Pharmacology and experimental therapeutics Vol. V. No. 6, July, 1914. Transfus Sci. 1990;11(2): 166–77.
  • Schröder A, Linker RA, Gold R. Plasmapheresis for neurological disorders. Expert Rev Neurother. 2009;9(9):1331–1339.
  • Padmanabhan A, Connelly-Smith L, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the American society for apheresis: the eighth special issue. J Clin Apher. 2019;34:171–354.
  • Chodankar D. Introduction to real-world evidence studies. Perspect Clin Res. 2021;12:171.
  • Henriksson MM, Newman E, Witt V, et al. Adverse events in apheresis: an update of the WAA registry data. Transfus Apher Sci. 2016;54:2–15.
  • Osman C, Jennings R, El-Ghariani K, et al. Plasma exchange in neurological disease. Pract Neurol. 2019;0:1–10.
  • Connelly-Smith L, Dunbar NM. The 2019 guidelines from the American society for apheresis. Curr Opin Hematol. 2019;26:461–465.
  • Van den Bergh PYK, van Doorn Pa, Hadden RDM, et al. European Academy of neurology/peripheral nerve society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task Force—Second revision. Eur J Neurol. 2021;28(11):3556–3583.
  • Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2017;2017(3). DOI:10.1002/14651858.CD001798.pub3
  • Gajdos P, Chevret S, Toyka K. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev. 2012;12:511–514.
  • Dyck PJ, Litchy WJ, Kratz KM, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 1994;36(6):838–845.
  • Cortese I, Cornblath DR. Therapeutic plasma exchange in neurology: 2012. J Clin Apher. 2013;28(1):16–19.
  • Nosadini M, Mohammad SS, Ramanathan S, et al. Immune therapy in autoimmune encephalitis: a systematic review. Expert Rev Neurother. 2015;15(12):1391–1419.
  • Rønager J, Ravnborg M, Hermansen I, et al. Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis. Artif Organs. 2001;25(12):967–973.
  • Nagpal S, Benstead T, Shumak K, et al. Treatment of Guillain-Barre syndrome: a cost-effectiveness analysis. J Clin Apher. 1999;14(3):107–113.
  • Winters JL, Brown D, Hazard E, et al. Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barré syndrome. BMC Health Serv Res. 2011;11(1):101.
  • Klemencic Kozul T, Yudina A, Donovan C, et al. Cost-minimisation analysis of plasma exchange versus IVIg in the treatment of autoimmune neurological conditions. BMC Health Serv Res. 2022;22(1):22.
  • Heatwole C, Johnson N, Holloway R, et al. Plasma exchange vs. intravenous immunoglobulin for myasthenia gravis crisis: an acute hospital cost comparison study. J Clin Neuromuscul Dis. 2011;13(2):85–94. DOI:10.1097/CND.0b013e31822c34dd
  • Ebadi H, Barth D, Bril V. Safety of plasma exchange therapy in patients with myasthenia gravis. Muscle Nerve. 2013;47(4):510–514.
  • Okafor C, Ward DM, Mokrzycki MH, et al. Introduction and overview of therapeutic apheresis. J Clin Apher. 2010;25(5):240–249.
  • Norda R, Stegmayr BG, Swedish Apheresis Group. Therapeutic apheresis in Sweden: update of epidemiology and adverse events. Transfus Apher Sci. 2003;29(2):159–166.
  • Nieto-Aristizábal I, Vivas ÁJ, Ruiz-Montaño P, et al. therapeutic plasma exchange as a treatment for autoimmune neurological disease. Autoimmune Diseases. 2020;2020:1–6.
  • Klingele M, Allmendinger C, Thieme S, et al. therapeutic apheresis within immune-mediated neurological disorders: dosing and its effectiveness. Scientific Reports. 2020;10(1). DOI:10.1038/s41598-020-64744-4

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.